Navigation Links
Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
Date:2/17/2009

ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that GlaxoSmithKline (NYSE: GSK) has initiated a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria(R) (albiglutide) in the long-term treatment of type 2 diabetes mellitus. As a result, HGS will receive a $9 million milestone payment in the first quarter of 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"We are delighted that GSK has advanced Syncria to Phase 3 development, and we look forward to the future progress of this important program," said H. Thomas Watkins, President and Chief Executive Officer, HGS.

Syncria is the fifth product to which HGS has substantial financial rights that has entered late-stage clinical development. It is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million - including $24 million received to date - in addition to single-digit royalties on worldwide sales if Syncria is commercialized.

Attached is a press release issued earlier this morning by GSK (http://tinyurl.com/crprkt) announcing initiation of the Phase 3 program for Syncria. All inquiries regarding the dev
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
2. 14th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging
3. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
4. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
5. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
6. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
7. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
8. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
9. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... million which brings Q3 orders to $5.8 million and provides a ... projects in North America and one in ... to bid new projects at record levels," said Peter Bruijns ... higher at the end of Q3 than they have been for ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... today,announced strong revenue growth and stable net profits despite ... in the US was offset by a strong,performance from ... Darwazah, said "The US operations, in 2007, reported,operating profit ... loss there so in spite of,this $30m plus loss ...
... BioPharma Corp. (TSX, FSE: "HBP") today announced financial results for the second ... , , , ... U.S. Securities and Exchange Commission which became effective on March 12, 2009 ... , Helix received regulatory approval to ...
... TauTaTis, Inc. announces that its lead compound for inhibition ... Alzheimer,s Disease, has been recognized as the most potent ... LRRK2 reported to date. Mutations of this gene ... most genetic frequent cause of Parkinson,s Disease.TauTaTis, lead compound ...
Cached Biology Technology:Helix BioPharma Announces Q2 2009 Financial Results 2Helix BioPharma Announces Q2 2009 Financial Results 3Helix BioPharma Announces Q2 2009 Financial Results 4Helix BioPharma Announces Q2 2009 Financial Results 5Helix BioPharma Announces Q2 2009 Financial Results 6Helix BioPharma Announces Q2 2009 Financial Results 7Helix BioPharma Announces Q2 2009 Financial Results 8Helix BioPharma Announces Q2 2009 Financial Results 9Helix BioPharma Announces Q2 2009 Financial Results 10Helix BioPharma Announces Q2 2009 Financial Results 11Helix BioPharma Announces Q2 2009 Financial Results 12TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity 2
(Date:10/16/2014)... Virginia Institute of Marine Science have received a ... to identify the streams and wetlands most vulnerable ... help local governments and citizens conserve these important ... dataset of tidal-marsh observations first gathered by VIMS ... baseline can today,s researchers accurately map the slow ...
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... skates (skates made of animal bones) are the oldest ... BC. Why people started skating on ice and where ... in several locations spread across Central and North Europe. ... Journal of the Linnean Society of London, Dr Formenti ...
... not immediately engage in a race against time to save ... the global warming and acidification predicted for later this century. ... from around the world in a major new study published ... the public understands that the lack of sustainability in the ...
... MD The Biophysical Society has announced the winners of ... of the Biophysical Society and the International Biophysics Congress ... of this competitive award are selected based on scientific ... a paper at the conference. Each awardee receives ...
Cached Biology News:Major study concludes that global warming is killing off coral 2Biophysical Society announces winners of 2008 Student Travel Awards 2Biophysical Society announces winners of 2008 Student Travel Awards 3Biophysical Society announces winners of 2008 Student Travel Awards 4Biophysical Society announces winners of 2008 Student Travel Awards 5
... for the fast and simple integration of ... position (for the generation of transgenic mouse ... to allow neomycin / kanamycin selection in ... prokaryotic promoter (gb2) for expression of kanamycin ...
Includes a choice of any 3 EasySep mouse selection kits and EasySep magnet...
... These 1.5L PYREX trypsinizing flasks ... tissue samples into cell suspensions ... Heavy beaded neck accepts cotton ... vigorous agitation. • Height of ...
... Application: For the efficient enrichment ... mammalian tissue or cell culture. The ... synthesis, degradation and metabolic pathway analysis. ... acetyltransferase deficiency in children, cystic fibrosis ...
Biology Products: